NeoGenomics, Inc. (ADR)
General ticker "NEO" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $234.4M (TTM average)
NeoGenomics, Inc. (ADR) follows the US Stock Market performance with the rate: 42.7%.
Estimated limits based on current volatility of 2.5%: low 13.98$, high 14.70$
Factors to consider:
- Earnings expected soon, date: 2026-07-28 amc
- Total employees count: 2500 (+13.6%) as of 2025
- Top business risk factors: Labor/talent shortage/retention, Technological changes, Capacity constraints, Litigation risks, Supply chain disruptions
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.21$, 19.28$]
- 2026-12-31 to 2027-12-31 estimated range: [11.28$, 19.37$]
Financial Metrics affecting the NEO estimates:
- Positive: with PPE of 302.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0.10 <= 0.28
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.21 <= 3.34
- Positive: -4.39 < Investing cash flow per share per price, % of -3.98
- Positive: Inventory ratio change, % of -0.06 <= 0
- Positive: 42.57 < Shareholder equity ratio, % of 61.52 <= 64.23
- Negative: negative Industry operating cash flow (median)
Short-term NEO quotes
Long-term NEO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $591.64MM | $660.57MM | $727.33MM |
| Operating Expenses | $699.38MM | $752.67MM | $843.21MM |
| Operating Income | $-107.74MM | $-92.11MM | $-115.88MM |
| Non-Operating Income | $10.64MM | $11.43MM | $5.61MM |
| Interest Expense | $6.91MM | $6.62MM | $3.75MM |
| R&D Expense | $27.31MM | $31.16MM | $37.08MM |
| Income(Loss) | $-97.10MM | $-80.67MM | $-110.27MM |
| Taxes | $-9.13MM | $-1.95MM | $-2.24MM |
| Net Income(Loss)* | $-87.97MM | $-78.73MM | $-108.03MM |
| Stockholders Equity | $941.54MM | $902.34MM | $836.56MM |
| Inventory | $24.16MM | $26.75MM | $28.57MM |
| Assets | $1,681.23MM | $1,638.04MM | $1,359.83MM |
| Operating Cash Flow | $-1.95MM | $7.02MM | $5.23MM |
| Capital expenditure | $28.75MM | $41.06MM | $27.01MM |
| Investing Cash Flow | $76.71MM | $12.86MM | $-12.34MM |
| Financing Cash Flow | $4.55MM | $4.65MM | $-200.29MM |
| Earnings Per Share** | $-3.50 | $-3.11 | $-4.22 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.